

Curriculum Vitae

DARKO ANTIC, MD, PhD, Date of birth 15.10.1976.

BUSINESS ADDRESS

Clinic for Hematology, Clinical Center Serbia
Medical Faculty University of Belgrade
Koste Todorovica 2, 11000 Belgrade, SERBIA
PHONE +381 63 63 47 47
EMAIL darko.antic1510976@gmail.com

SUMMARY

Lymphoproliferative diseases with focus on Chronic Lymphocytic Leukemia; Thrombosis in cancer patients; Teaching; Integrative studies; Systematic reviews and meta-analysis; Health management

PROFFESIONAL DETAILS

- 2020. -current**, Head, Clinic for Hematology, Clinical Center of Serbia
- 2022. -current**, Head of Department for CLL, Clinic for Hematology, Clinical Center of Serbia
- 2021. -current** National Immunization Technical Advisory Groups
- 2019. – 2022.**, member of Central Ethics Committee /responsible for clinical trials/
- 2017- 2020** Deputy Director, Clinic for Hematology, Clinical Center of Serbia
- 2018.- 2022.**, Clinical oncology, course Director, Medical Faculty University of Belgrade. Studies in English
- 2018.- current**, Assistant Professor of Internal medicine, Medical Faculty University of Belgrade
- 2015- current**, President of Serbian Lymphoma Group
- 2014-2022**, Head of Intensive care unit, Lymphoma Centre, Clinic for Hematology, Clinical Center of Serbia
- 2011-2018**, Teaching Assistant of Internal medicine, Medical Faculty University of Belgrade
- 2016-current**, National representative and member of European Research Initiative on CLL (ERIC)
- 2015-2016**, National representative of International Society of Geriatric Oncology (SIOG)

EDUCATION

- 2001**, MD Medical Faculty University of Belgrade
- 2004**, MSci Hematology (Hodgkin Lymphoma) , Medical Faculty University of Belgrade
- 2006**, Internal medicine specialist, Medical Faculty University of Belgrade,
- 2009**, Subspecialist Hematology , Medical Faculty University of Belgrade
- 2010**, PhD Hematology (Chronic Lymphocytic Leukemia) , Medical Faculty University of Belgrade
- 2016**, Master manager of Health Care Management, Medical Faculty University of Belgrade
- March – May 2016**, International scientific visit and knowledge exchange at AKH Vienna, Austria

INTERNATIONAL SPEAKER EXPERIENCE

2021

EHA 2021: *THROLY score successfully classifies Hodgkin lymphoma patients at risk of thromboembolic complications – project with German Hodgkin Study group*

2019

26th Anniversary International Congress European and Mediterranean League against Thromboembolic Disease

Chair of plenary session: *Challenges in Prevention and Treatment of Cancer-Associated Thrombosis*

Oral presentation: *Biomarkers of hemostatic dysregulation and inflammation in lymphoma. Potential relevance to thrombogenesis*

2018:

International Conference on Thrombosis and Hemostasis Issues in Cancer 2018: *Internal and external validation of THROLY (thrombosis lymphoma) score*

ASH 2018: *External Validation and Revision of Thrombosis Lymphoma Score /Throly score/ - mutal project with EHA lymphoma group*

2017:

Loyola university, Chicago: *Cancer and thrombosis*

ASH 2017 : *Development and External Validation of Thrombosis Lymphoma /Throly/ Score - Interim Analysis*

EHA 2017: *Comparative analysis of predictive models for thromboembolic events in lymphoma patients*

2016:

EHA 2016: *Decoding the risk of thromboembolic events in lymphoma patients*

International Conference on Thrombosis and Hemostasis Issues in Cancer 2016: *Decoding risk for thromboembolic events in lymphoma patients*

2015:

EHA 2015: *Development of a predictive score for the identification of lymphoma patients at risk for thromboembolism*

ERIC ACTIVITIES:

Member of research group for definition of new biomarkers in patients with CLL

Leader of Cell Biobanking project for Serbia

Local organizer of the meeting „International workshop biomarkers in chronic lymphocytic leukemia: the art of synthesis“ - March 2018, Belgrade:

Current multicentric project: CLL, COVID 19 and thrombosis

ITAC ACTIVITIES

2021. The International Initiative on Thrombosis and Cancer (ITAC): vice chair

Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brillhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019

EHA ACTIVITIES

2021. member of EHA taskforce on diversity, equity and inclusion

SERBIAN LYMPHOMA GROUP ACTIVITIES:

2016-2017. National Guidelines for Diagnostics and Treatment of B Cell Malignancies: initiator of the project and coordinator of working group engaged in production and publishing

2017- current, National CLL registry development: leader of the project

2015-2018., Collaboration and multiple joint activities with LIPA (Association of Patients with Lymphoma)

2021. National Guidelines for Diagnostics and Treatment of B Cell Malignancies: initiator of the project and coordinator of working group engaged in production and publishing - 2nd edition

AWARDS

2008, Clinical experience in treatment of uncontrolled bleeding with rFVIIa, Belgrade, Serbia

2010, Young Investigators meeting for CLL, Cologne, Germany

2012, Salzburg Weill Cornell Seminar, Academic excellence

2012, Salzburg Weill Cornell Seminar, Excellent case presentation

2018, Award for scientific work, Medical Faculty University of Belgrade

ISTH SSC ACTIVITIES:

Delluc A, **Antic D**, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2017

Wang TF, Zwicker JJ, Ay C, Pabinger I, Falanga A, **Antic D**, Noble S, Khorana AA, Carrier M, Meyer G. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost. 2019

Wang TF, Makar RS, **Antic D**, Levy JH, Douketis JD, Connors JM, Carrier M, Zwicker JJ. Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. J Thromb Haemost. 2020

FULL PUBLICATIONS:

1. **Antic D**, Milic N, Chatzikonstantinou T, Scarfò L, Otasevic V, Rajovic N, Allsup D, Alonso Cabrero A, Andres M, Baile Gonzales M, Capasso A, Collado R, Cordoba R, Cuéllar-García C, Correa JG, De Paoli L, De Paolis MR, Del Poeta G, Dimou M, Doubek M, Efstathopoulou M, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Lopez-Garcia A, García-Marco JA, García-Serra R, Gentile M, Gimeno E, da Silva MG, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicińska E, Kater AP, Kersting S, Koren-Michowitz M, Labrador J, Lad D, Laurenti L, Fresa A, Levin MD, Mayor Bastida C, Malerba L, Marasca R, Marchetti M, Marquet J, Mihaljevic B, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Nunes R, Olivieri J, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Reda G, Rigolin GM, Shrestha A, Šimkovič M, Smirnova S, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Te Raa D, Tomic K, Tonino S, Trentin L, Van Der Spek E, van Gelder M, Varettoni M, Visentin A, Vitale C, Vukovic V, Wasik-Szczepanek E, Wróbel T, Segundo LYS, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Carrier M, Ghia P, Stamatopoulos K. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. *J Hematol Oncol*. 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0.
2. Tosic N, Ugrin M, Marjanovic I, Kostic T, Vukovic V, Tomic K, Otasevic V, **Antic D**, Mihaljevic B, Pavlovic S, Karan-Djurasevic T. Expression of BCL11A in chronic lymphocytic leukaemia. *Int J Lab Hematol*. 2022 Sep 19. doi: 10.1111/ijlh.13969.
3. Farge, D., Frere, C., Connors, J. M., Khorana, A. A., Kakkar, A., Ay, C., Muñoz, A., Brenner, B., Prata, P. H., Brilhante, D., **Antic, D.**, Casais, P., Guillermo Esposito, M. C., Ikezoe, T., Abutalib, S. A., Meillon-García, L. A., Bounameaux, H., Pabinger, I., Douketis, J., & International Initiative on Thrombosis and Cancer (ITAC) advisory panel (2022). 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. *The Lancet. Oncology*, 23(7), e334–e347.
4. Mitrović Ajić, O., Subotički, T., Diklić, M., Đikić, D., Vukotić, M., Dragojević, T., Živković, E., **Antić, D.**, & Čokić, V. (2022). Regulation of S100As Expression by Inflammatory Cytokines in Chronic Lymphocytic Leukemia. *International journal of molecular sciences*, 23(13), 6952.
5. Otasevic, V., Mihaljevic, B., Milic, N., Stanisavljevic, D., Vukovic, V., Tomic, K., Fareed, J., & **Antic, D.** (2022). Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. *Thrombosis journal*, 20(1), 20.
6. Pekic, S., Stojanovic, M., Manojlovic Gacic, E., **Antic, D.**, Milojevic, T., Milicevic, M., Stanimirovic, A., Doknic, M., Miljic, D., Banjalic, S., Jovanovic, M., Jemuovic, Z., Nikolic Djurovic, M., Grujicic, D., Popovic, V., & Petakov, M. (2022). The sellar region as presenting theater for hematologic malignancies-A 17-year single-center experience. *Endocrine journal*, 10.1507/endocrj.EJ21-0790.
7. **Antic D**, Lefkou E, Otasevic V, et al. Position Paper on the Management of Pregnancy-Associated Superficial Venous Thrombosis. Balkan Working Group for Prevention and Treatment of Venous Thromboembolism. *Clin Appl Thromb Hemost*. 2022;28:1076029620939181. doi:10.1177/1076029620939181
8. Chatzikonstantinou T, Kapetanakis A, Scarfò L, **Antic D** et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. *Leukemia*. 2021;35(12):3444-3454.
9. Mitrovic M, Sabljic N, Cvetkovic Z, Pantic N, Zivkovic Dakic A, Bukumiric Z, Libek V, Savic N, Milenkovic B, Virijevec M, Vucinic V, Milosevic I, Pravdic Z, Suvajdzic N, Fareed J, **Antic D**. Rotational Thromboelastometry (ROTEM) Profiling of COVID-19 Patients. *Platelets*. 2021:1-7.
10. Wang TF, Makar RS, **Antic D**, Levy JH, Douketis JD, Connors JM, Carrier M, Zwicker JI. Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. *J Thromb Haemost*. 2020 ;18(12):3174-3183.
11. Siddiqui F, **Antic D**, Tafur A, Bontekoe E, Hoppensteadt D, Gerotziafas G, Elalamy I, Fareed J. Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa. *Clin Appl Thromb Hemost*. 2020 Jan-Dec;26:1076029620983466. doi: 10.1177/1076029620983466.
12. Agathangelidis A, Chatzidimitriou A, Gemenetzi K, **Antic D** et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL [published online ahead of print, 2020 Sep 29]. *Blood*. 2020;blood.2020007039. doi:10.1182/blood.2020007039
13. Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic DM, Farkas K, Elalamy I, Falanga A, Fareed J, Papageorgiou C, Arellano RS, Agathagelou P, **Antic D**, et al. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. *Thromb Haemost*. 2020;120(12):1597-1628.
14. Gerotziafas GT, Mahé I, Lefkou E, AboElnazar E, Abdel-Razeq H, Taher A, **Antic D**, Elalamy I, Syrigos K, Van Dreden P. Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer. *Thromb Res*. 2020 Jul;191 Suppl 1:S50-S57.
15. Mato AR, Roeker LE, Lamanna N, Antic D. et al. Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience. *Blood*. 2020 136(10):1134-1143.

16. Wang TF, Zwicker JJ, Ay C, Pabinger I, Falanga A, **Antic D**, Noble S, Khorana AA, Carrier M, Meyer G. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. *J Thromb Haemost*. 2019 ;17(10):1772-1778.
17. Vukovic V, Karan-Djurasevic T, **Antic D**, et al. Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients. *Pathol Oncol Res*. 2020;26(2):743-752.
18. Mihaljevic B, Smiljanic M, **Antic D**, Kurtovic NK, Balint MT. Chronic Lymphocytic Leukemia Involvement of Central Nervous System: Clinical Diversity, Diagnostic Algorithm and Therapeutic Challenges. *Ann Indian Acad Neurol*. 2018;21(1):85-87.
19. **Antic D**, Jelcic J, Trajkovic G, Balint MT, Bila J, Markovic O, Petkovic I, Nikolic V, Andjelic B, Djurasinovic V, Sretenovic A, Smiljanic M, Vukovic V, Mihaljevic B. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities. *Ann Hematol*. 2018;97(2):267-276.
20. **Antic D**, Jelcic J, Vukovic V, Nikolovski S, Mihaljevic B. Venous thromboembolic events in lymphoma patients: Actual relationships between epidemiology, mechanisms, clinical profile and treatment. *Blood Rev* 2018;32(2):144-158.
21. Bila J, Jelcic J, Dencic Fekete M, Trajkovic G, Sretenovic A, Perunicic Jovanovic M, **Antic D**, Mihaljevic B. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients. *Oncol Res Treat*. 2017;40(10):616-620.
22. Delluc A, **Antic D**, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2017;15(10):2076-2079.
23. Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt T, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Djurasevic T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, **Antic D**, Trentin L, Montillo M, Niemann C, Döhner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. *Clin Cancer Res*. 2017 ;23(17):5292-5301.
24. Markovic O, Andjelic B, Tarabar O, Todorovic M, Filipovic B, Stanisavljevic D, Bila J, **Antic D**, Marisavljevic D, Mihaljevic B. Late relapse of Hodgkin's lymphoma - is it different in clinical characteristics and outcome? *J BUON*. 2017;22(2):481-486.
25. Bodrozic JN, Miljic PS, Lekovic DR, Petronijevic MA, **Antic DA**, Mitrovic MM, Petronijevic-Vrzic SM, Djunic IS. Pregnancy and delivery in a woman with severe haemophilia A. *Blood Coagul Fibrinolysis*. 2017;28(6):496-499.
26. Mihaljevic B, Jelcic J, Andjelic B, **Antic D**, Markovic O, Petkovic I, Jovanovic MP, Trajkovic G, Bila J, Djurasinovic V, Sretenovic A, Vukovic V, Smiljanic M, Balint MT. FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma. *Int J Hematol*. 2016;104(6):692-699.
27. **Antic D**, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Jelcic J, Hayman S, Mihaljevic B. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. *Am J Hematol*. 2016;91(10):1014-9.
28. Todorovic Balint M, Jelcic J, Mihaljevic B, Kostic J, Stanic B, Balint B, Pejanovic N, Lucic B, Tosic N, Marjanovic I, Stojiljkovic M, Karan-Djurasevic T, Perisic O, Rakocevic G, Popovic M, Raicevic S, Bila J, **Antic D**, Andjelic B, Pavlovic S. Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses. *Int J Mol Sci*. 2016;17(5).
29. Jelcic J, Balint MT, Jovanovic MP, Boricic N, Micev M, Stojic J, **Antic D**, Andjelic B, Bila J, Balint B, Pavlovic S, Mihaljevic B. The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and High CD44 Tumor Cell Expression in Non Hodgkin Lymphomas. *Pathol Oncol Res*. 2016;22(3):567-77.
30. Jelcic J, Todorovic Balint M, Raicevic S, Ilic R, Stanisavljevic D, Bila J, **Antic D**, Balint B, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Mihaljevic B. The possible benefit from total tumour resection in primary diffuse large B-cell lymphoma of central nervous system - a one-decade single-centre experience. *Br J Neurosurg*. 2016;30(1):80-5.
31. Jelcic J, Todorovic Balint M, **Antic D**, Sretenovic A, Balint B, Perunicic Jovanovic M, Andjelic B, Vukovic V, Djurasinovic V, Bila J, Pavlovic M, Smiljanic M, Mihaljevic B. Enhanced International Prognostic Index (NCCN-IPI), Charlson Comorbidity Index and absolute lymphocyte count as predictors for survival of elderly patients with diffuse large B cell lymphoma treated by immunochemotherapy. *Neoplasma*. 2015;62(6):988-95.
32. **Antic D**, Bogdanovic A, Perunicic Jovanovic M, Jovanovic J, Elezovic I. Myeloid sarcoma of the skin in a patient with myelodysplastic syndrome. *Acta Dermatovenerol Croat*. 2015;23(2):134-7.
33. Jovanovic MP, Mihaljevic B, Jakovic L, Martinovic VC, Fekete MD, Andjelic B, **Antic D**, Bogdanovic A, Boricic N, Terzic T, Jelcic J, Milenkovic S. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes. *J BUON*. 2015;20(3):820-8.
17. Bila J, Jelcic J, Djurasinovic V, Vukovic V, Sretenovic A, Andjelic B, **Antic D**, Todorovic M, Mihaljevic B. Prognostic effect of comorbidity indices in elderly patients with multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2015;15(7):416-9.
18. **Antic D**, Jelcic J, Vukovic V, Pupic G, Milovanovic Z, Mihaljevic B. Concomitant chronic lymphocytic leukemia and Merkel cell carcinoma. *Dermatologica Sinica*. 2015;33(3): 166-169.
19. Simonović O, Mačukanović-Golubović L, Anđelić B, **Antić D**, Mihaljević B. Serbian lymphoma study group (SLG): demographic and epidemiological presentation of 257 patients with follicular lymphoma. *Vojnosanit Pregl*. 2015;72(6):483-8.

20. Andjelić B, Todorović M, **Antić D**, Bila J, Djurasinović V, Mihaljević B. Follicular Lymphoma Patients With a High FLIPI Score and High Tumor Burden: a Risk Stratification Model. *Vojnosanit Pregl.* 2015;72(1):26-32.
21. Andjelic B, **Antić D**, Jakovic L, Todorovic M, Bogdanovic A, Djurasinovic V, Bila J, Mihaljevic B. A Single Institution Experience on 314 Newly Diagnosed Advanced Hodgkin Lymphoma Patients: The Role of ABVD in Daily Practice. *Eur J Haematol.* 2014;93(5):392-9.
22. Mitrović M, Elezović I, Miljić P, **Antić D**. Ginekološko akušerske intervencije kod žena sa Bernar-Sulijeovim sindromom – prikaz dve bolesnice. *Srp Arh Celok Lek.* 2014;142(5-6):351-5.
23. Djunic I, Elezovic I, Ilic V, Milosevic-Jovcic N, Bila J, Suvajdzic-Vukovic N, **Antić D**, Vidovic A, Tomin D. The effect of paraprotein on platelet aggregation. *J Clin Lab Anal.* 2014;28(2):141-6.
24. **Antić D**, Perunicic-Jovanovic M, Knezevic Dj, Ostojic S, Elezovic I. Progressive course of isolated splenic myeloid sarcoma. *Cent Eur J Med.* 2013;8(4):499-502.
25. Smiljanic M, Milosevic R, **Antić D**, Andjelic B, Djurasinovic V, Todorovic M, Bila J, Bogdanovic A, Mihaljevic B. Orbital and ocular adnexal Mucosa-Associated Lymphoid Tissue (MALT) lymphomas: a single-center 10-year experience. *Med Oncol.* 2013;30(4):722.
26. **Antić D**, Petrovic N, Pelemis M, Stevanovic G, Perunicic M, Mihaljevic B. "Invisible" primary cutaneous diffuse large B-cell lymphoma, leg type, as a cause of fever of unknown origin. *J Clin Oncol.* 2013;31(17):e276-9.
27. Djunic I, Elezovic I, Vucic M, Srdic-Rajic T, Konic-Ristic A, Ilic V, Milic N, Bila J, Suvajdzic-Vukovic N, Virijevec M, **Antić D**, Vidovic A, Tomin D. Specific binding of paraprotein to platelet receptors as a cause of platelet dysfunction in monoclonal gammopathies. *Acta Haematol.* 2013;130:101-7.
28. **Antić D**, Elezovic I, Milic N, Suvajdzic N, Vidovic A, Perunicic M, Djunic I, Mitrovic M, Tomin D. Is there a "gold" standard treatment for patients with isolated myeloid sarcoma? *Biomed Pharmacother.* 2013;67(1):72-7.
29. Karan-Djurasevic T, Palibrk V, Kostic T, Spasovski V, Nikcevic G, Srzentic S, Colovic M, Colovic N, Vidovic A, **Antić D**, Mihaljevic B, Pavlovic S, Tosic N. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia. *Clin Lymphoma Myeloma Leuk.* 2012;12(4):252-60.
30. **Antić D**, Impera L, Fekete MD, Djordjevic V, Storlazzi CT, Elezovic I. Novel chromosomal translocation (17;22)(q12;q12) in a case of myelodysplastic syndrome characterized with signs of hemolytic anemia at presentation. *Gene.* 2012 ;493(1):161-4.
31. Mitrović M, Elezović I, Suvajzić-Vuković N, **Antić D**. Successful non-standard approaches to massive hemoptysis in invasive pulmonary aspergillosis. *Srp Arh Celok Lek.* 2012;140(7-8):505-7.